Pier Capital’s Cytokinetics CYTK Stock Holding History

Pier Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.02M	Buy	70,665 +1,082	+2%	+$77.7K	0.8%	62
2026 Q1	$4.59M	Buy	+69,583	New	+$4.42M	0.76%	70

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pier Capital's CYTK Position: Q2 2026 in Review

Pier Capital increased its Cytokinetics (CYTK) stake by 1.6% in Q2 2026, buying an estimated $77.7K and bringing the position to 70,665 shares worth $6.02M. The position accounts for 0.8% of the portfolio, ranked #62.

Pier Capital first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Pier Capital held 70,665 shares of Cytokinetics worth $6.02M as of Q2 2026.
Pier Capital bought 1,082 Cytokinetics shares in Q2 2026, an estimated $77.7K.
Cytokinetics made up 0.8% of Pier Capital's portfolio in Q2 2026, its #62 holding.
Pier Capital first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.